{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:49Z","timestamp":1787009029936,"version":"build-2736575974"},"reference-count":22,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"internal funding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine clinical outcomes associated with aminoglycosides versus other antimicrobial agents as empirical treatment of hospitalized patients with pyelonephritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>An institutional programme promoting aminoglycosides as empirical treatment of pyelonephritis was implemented in 2016. We reviewed the hospital records of patients with pyelonephritis from January 2017 to April 2019. The primary outcome was death within 30\u2009days of index culture. Initial treatment with aminoglycoside-based regimens was compared with non-aminoglycoside antibiotics. Propensity score matching was performed to adjust for between-group differences in baseline covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study cohort included 2026 patients, 715 treated with aminoglycosides and 1311 treated with non-aminoglycoside drugs (ceftriaxone, n\u2009=\u2009774; piperacillin\/tazobactam, n\u2009=\u2009179; carbapenems, n\u2009=\u2009161; and fluoroquinolones, n\u2009=\u2009133); 589 patients (29%) had bloodstream infections. Treatment with aminoglycosides was associated with a higher likelihood of in vitro activity against clinical isolates (OR\u2009=\u20092.0; P\u2009&amp;lt;\u20090.001). Death at 30\u2009days occurred in 55 (7.6%) versus 145 (11%) patients treated with aminoglycosides and non-aminoglycoside drugs, respectively (adjusted HR\u2009=\u20090.78; P\u2009=\u20090.013). Aminoglycosides were either superior or similar to comparator drugs in all patient subgroups, stratified according to age, glomerular filtration rate, bacteraemia, haemodynamic shock and infection with third-generation cephalosporin-resistant Enterobacteriaceae. The incidence of acute kidney injury was similar for aminoglycosides and comparators (2.5% versus 2.9%, respectively; P\u2009=\u20090.6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within the context of an institutional programme, initial empirical treatment of pyelonephritis with aminoglycosides was associated with higher rates of in vitro activity and lower overall mortality compared with non-aminoglycoside drugs, without excess nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaa148","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:11:52Z","timestamp":1585325512000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis"],"prefix":"10.1093","author":[{"given":"Meital","family":"Elbaz","sequence":"first","affiliation":[{"name":"Internal Medicine, Tel Aviv Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hila","family":"Zadka","sequence":"first","affiliation":[{"name":"Data Science and Quality Division, Tel Aviv Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Weiss-Meilik","sequence":"first","affiliation":[{"name":"Data Science and Quality Division, Tel Aviv Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Ben-Ami","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Tel Aviv Medical Center, Tel Aviv, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"2020052523594965000_dkaa148-B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/318850","article-title":"Urinary tract infections: disease panorama and challenges","volume":"183 Suppl 1","author":"Stamm","year":"2001","journal-title":"J Infect Dis"},{"key":"2020052523594965000_dkaa148-B2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00345-013-1167-3","article-title":"Predictors of admission in patients presenting to the emergency department with urinary tract infection","volume":"32","author":"Sammon","year":"2014","journal-title":"World J Urol"},{"key":"2020052523594965000_dkaa148-B3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/02813432.2017.1333321","article-title":"Clinical indications for antibiotic use in Danish general practice: results from a nationwide electronic prescription database","volume":"35","author":"Aabenhus","year":"2017","journal-title":"Scand J Prim Health Care"},{"key":"2020052523594965000_dkaa148-B4","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/jac\/dkx146","article-title":"Global epidemiology of CTX-M \u03b2-lactamases: temporal and geographical shifts in genotype","volume":"72","author":"Bevan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020052523594965000_dkaa148-B5","doi-asserted-by":"crossref","first-page":"e3694","DOI":"10.1097\/MD.0000000000003694","article-title":"Bacteremic urinary tract infection caused by multidrug-resistant Enterobacteriaceae are associated with severe sepsis at admission","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2020052523594965000_dkaa148-B6","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020052523594965000_dkaa148-B7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020052523594965000_dkaa148-B8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.diagmicrobio.2011.03.021","article-title":"Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010","volume":"70","author":"Hoban","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020052523594965000_dkaa148-B9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt1977223364","article-title":"Renal clearance and tissue accumulation of gentamicin","volume":"22","author":"Schentag","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"2020052523594965000_dkaa148-B10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020052523594965000_dkaa148-B11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1445-5994.2011.02452.x","article-title":"Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity","volume":"41","author":"Avent","year":"2011","journal-title":"Intern Med J"},{"key":"2020052523594965000_dkaa148-B12","doi-asserted-by":"crossref","first-page":"e02165","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052523594965000_dkaa148-B13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2020052523594965000_dkaa148-B14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"2020052523594965000_dkaa148-B15","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure \u2013 definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"2020052523594965000_dkaa148-B16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2020052523594965000_dkaa148-B17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/cb3005116","article-title":"Aminoglycoside antibiotics in the 21st century","volume":"8","author":"Becker","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2020052523594965000_dkaa148-B18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1592\/phco.21.5.443.34490","article-title":"Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs","volume":"21","author":"Streetman","year":"2001","journal-title":"Pharmacotherapy"},{"key":"2020052523594965000_dkaa148-B19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkl288","article-title":"Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team","volume":"58","author":"Zahar","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020052523594965000_dkaa148-B20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy versus \u03b2-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020052523594965000_dkaa148-B21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2020052523594965000_dkaa148-B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/149.1.23","article-title":"Risk factors for the development of auditory toxicity in patients receiving aminoglycosides","volume":"149","author":"Moore","year":"1984","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa148\/33294351\/dkaa148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa148\/33294351\/dkaa148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:02Z","timestamp":1590451202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkaa148\/5843906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa148","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"article-number":"dkaa148"}}